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Fecal microbiota transplantation (FMT) is a promising therapy, despite some reports of
adverse side effects. Bacterial consortia transplantation (BCT) for targeted restoration of
the intestinal ecosystem is considered a relatively safe and simple procedure. However,
no systematic research has assessed the effects of FMT and BCT on immune responses
of intestinal mucosal barrier in patients. We conducted complementary studies in animal
models on the effects of FMT and BCT, and provide recommendations for improving the
clinical outcomes of these treatments. To establish the dysbiosis model, male BALB/c
mice were treated with ceftriaxone intra-gastrically for 7 days. After that, FMT and
BCT were performed on ceftriaxone-treated mice for 3 consecutive days to rebuild
the intestinal ecosystem. Post-FMT and post-BCT changes of the intestinal microbial
community and mucosal barrier functions were investigated and compared. Disruption
of intestinal microbial homeostasis impacted the integrity of mucosal epithelial layer,
resulting in increased intestinal permeability. These outcomes were accompanied by
overexpression of Muc2, significant decrease of SIgA secretion, and overproduction
of defensins and inflammatory cytokines. After FMT and BCT, the intestinal microbiota
recovered quickly, this was associated with better reconstruction of mucosal barriers
and re-establishment of immune networks compared with spontaneous recovery (SR).
Although based on a short-term study, our results suggest that FMT and BCT promote
the re-establishment of intestinal microbial communities in mice with antibiotic-induced
dysbiosis, and contribute to the temporal and spatial interactions between microbiota
and mucosal barriers. The effects of BCT are comparable to that of FMT, especially in
normalizing the intestinal levels of Muc2, SIgA, and defensins.
Keywords: intestinal dysbiosis, fecal microbiota transplantation, bacterial consortia transplantation, mucosal
barrier function, intestinal microbiota
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Introduction
Commensal bacteria living in the human gastrointestinal tract
provide a biological barrier against the invasion of pathogens
and contribute to the modulation of the immune system
(Hooper et al., 2012; Maynard et al., 2012). Disturbance
of intestinal microbiota may result in dysfunction of the
mucosal barrier, as it has been shown in animal models
that treatment of antibiotics altered the colonic mucus layer
(Wlodarska et al., 2011), increased bacterial translocation (Wang
et al., 2014), and led to intestinal sensory and motor changes
(Aguilera et al., 2015). Intestinal microbes have been proved
to aﬀect mucin gene expression (Becker et al., 2013), mucosal
permeability, secretion of secretory immunoglobulin A (SIgA)
and antibacterial peptides, as well as of various cytokines by cells
on mucosal surfaces (Lutgendorﬀ et al., 2008). Dysfunction of
the intestinal barrier increases risk for infection and metabolic
disorders, which are closely related to a variety of gastrointestinal
diseases (Turner, 2009). Re-establishing the equilibrium of
the intestinal microbiota is therefore important for clinical
improvement in patients suﬀering from gastrointestinal diseases.
The use of probiotics can restore function to a disrupted
mucosal barrier (Dicksved et al., 2012). However, in patients
with intestinal dysbiosis—signiﬁcant qualitative and quantitative
changes in the intestinal microbiota (Hawrelak and Myers,
2004)—it can be diﬃcult to completely eradicate harmful
bacteria, and selectively restore and maintain a community
of healthy bacteria. Recently, fecal microbiota transplantation
(FMT) has received much public attention (van Nood et al.,
2013). Because of the high cure rate (over 90%) and rare
occurrence of side eﬀects, FMT has been considered a potentially
life-saving “last chance” option for the treatment of recurrent
Clostridium diﬃcile infection (Bakken et al., 2011). This has
generated interest in applying this therapy to the treatment
of other gastrointestinal diseases. Several studies have reported
that infusion of fecal suspension from healthy individuals
to inﬂammatory bowel disease (IBD) (Bennet and Brinkman,
1989; Kunde et al., 2013; Kao et al., 2014) or irritable bowel
syndrome (IBS) (Konig and Brummer, 2014; Shanahan and
Quigley, 2014) patients resulted in clinical improvement and
remission. It has been suggested by many scientists that
FMT has promising therapeutic potential for the treatment of
diabetes (Udayappan et al., 2014), obesity, non-alcoholic fatty
liver disease (NAFLD), and even cardiovascular disease (Smits
et al., 2013). However, some studies have reported less than
ideal outcomes of FMT (Vermeire et al., 2012; Kump et al.,
2013), and signiﬁcant diﬀerences have been found regarding the
colonization of bacteria in the gastrointestinal tract of diﬀerent
patients (Angelberger et al., 2013). Some researchers have
attempted mixed bacterial consortium transplantation (BCT) to
re-establish the intestinal ecosystem in animalmodels of digestive
and metabolic diseases (Lawley et al., 2012). This method is
considered to have better control and to be relatively stable
(Petrof and Khoruts, 2014), and thus is worthy of in-depth
study. However, no systematic research has assessed the eﬀects
of FMT/BCT on immune responses of the intestinal mucosal
barrier in patients. In fact, colonization by donor bacteria and
changes of mucosal physiology in the human intestine can be
hard to achieve. Complementary studies of post-FMT or post-
BCT changes in animal models are important to improve clinical
eﬃcacy.
In this study, we induced intestinal dysbiosis in BALB/c
mice by using the broad-spectrum antibiotic ceftriaxone sodium,
which is widely used in China for the treatment of infections
in the respiratory and digestive tracts. Two bacteriotherapies,
FMT and BCT, were adopted to re-establish intestinal microbial
equilibrium. Post-FMT and post-BCT changes of the gut
mucosal barrier function in mouse models were investigated
and compared. This study helps our understanding of the
eﬀects of intestinal microbiota on mucosal barrier function
during occurrence, development, and prognosis of diseases,
and provides new insight into the development of microbiota
transplantation therapy.
Materials and Methods
Animals
Male BALB/c mice (aged 6–8 weeks, weighing 18 ± 22 g) were
provided by the Experimental Animal House of Dalian Medical
University, where they were maintained under speciﬁc pathogen-
free conditions (light/dark cycles of 12 h). All mice of the same
experimental conditions were co-housed in a ﬁlter top cage,
and given food and water ad libitum. To establish the dysbiosis
model, mice were treated with 0.2mL ceftriaxone sodium (400
mg/mL) intra-gastrically twice a day with an interval of 6 h for
7 days. For controls, sterile water was used. 30 mice were used
in each experimental group (total 120 mice), and they were
sacriﬁced by cervical dislocation after inhalational anesthesia at
indicated time point (Please see details of the animal tests in the
Figure S1). The animal experimental procedures were approved
by the Medical Ethics Committee of Dalian Medical University,
China (SYXK2012-0002).
Transplantation of Microbiota
For FMT: Fresh feces was collected from 5 healthy BALB/c
mice, homogenized in 10mL of sterile PBS and centrifuged
for 30 s at 3000 r.p.m., 4◦C, to pellet the particulate matter.
OD value of the supernatant slurry was checked to calculate
the concentration of total bacteria (OD = 0.5 represents 108
cells). For each mouse, 1 × 109.8 bacterial cells (sum of total
bacterial population within 2 g cecal contents) were centrifuged
for 5min at 12,000 r.p.m., 4◦C, the bacterial pellets was re-
suspended in 0.5mL PBS and gavaged into each mouse 1 day at a
time.
For BCT: Individual bacteria isolated from mouse feces were
grown in diﬀerent liquid medium (see Table 1) for 12–48 h
under aerobic or anaerobic conditions at 37◦C. Bacteria were
harvested by centrifugation and re-suspended in sterile PBS. The
density of each bacterium was measured through OD detection,
according to the population in mouse feces (Table 1), diﬀerent
volumes of bacteria were calculated and mixed to form the
bacterial consortium, all the cells were then centrifuged and re-
suspended in 0.5mL PBS and gavaged into each mouse 1 day at
a time.
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The control and SR mice were gavaged 0.5mL PBS 1 day at a
time. All mice were treated at the same time and dispatched in
diﬀerent groups.
Isolation and Quantitative Real-time PCR (qPCR)
Analysis of Commensal Bacteria in Mice
For isolation of strains, a mixture of feces from 10 individual
healthy mice was used. Feces were diluted with two volumes
of sterile phosphate-buﬀered saline (PBS) and homogenized by
vortex. The homogenized solutions were serially diluted in sterile
PBS ranging from 10−1 to 10−6. Diluted suspensions (20μL)
were plated on selective agar media (Table 1) and cultured at
37◦C. Single colonies were picked and identiﬁed by microscopy
and 16S rDNA sequencing; the sequences of the isolates were
deposited in NCBI GenBank under the accession number of
KM056276∼ KM056286.
The numbers of 11 selected bacterial groups in cecal contents
of mice were quantiﬁed using the Thermal Cycler Dice Real
Time SystemII (Takara, Japan). Ampliﬁcation and detection were
carried out in 96-well plates using SYBR R© Premix DimerEraser™
(Perfect Real Time, Takara, Japan). Each reaction was done
in triplicate in a 25μL total reaction mixture using 2μL of
appropriate dilutions of the DNA sample and 0.3mM ﬁnal
quantitative PCR primer concentration. The ampliﬁcation cycle
used was one cycle of 95◦C for 1min, followed by 50 cycles of
95◦C for 5 s, 55∼ 68◦C for 30 s, 72◦C for 30 s, and dissociation at
95◦C for 15 s, 60◦C for 30 s, and 95◦C for 15 s. For construction
of the standard curve, the PCR products were generated using
the standard PCR primers listed in Table 1 and genomic DNA of
diﬀerent isolates. The copy numbers of samples were determined
by reading oﬀ the standard series with the Ct values of the
samples as described previously (Eeckhaut et al., 2013). Gene
copy numbers were expressed as Log10 values per gram wet
weight of cecal contents.
Denaturing Gradient Gel Electrophoresis (DGGE)
Profiling
The metagenomic DNA was extracted from the frozen cecal
content of randomly selected mice (5/group) by the QIAamp
DNA stool mini kit (Qiagen, Germany). PCR was conducted
using universal primers F338+GC clamp and R518 targeting
the hypervariable V3 region of 16S rRNA gene. The resulting
16S rDNA amplicons were analyzed using the DCode system
(Bio-Rad, USA) according to descriptions of Joossens et al.
(2011). Digitized DGGE images were analyzed with Quantity
One image analysis software (version 4.6.1, Bio-Rad USA). To
identify speciﬁc bands, the DNA extraction and sequencing was
performed according to Joossens et al. (2011).
Collection of Biological Samples and Detection
of SIgA, Muc2, Defensins, and Cytokines
The ileum and colon were removed from mice. Five milli liter of
PBS (pH 7.2) containing 0.02% sodium azide was passed through
the intestinal segments in order to collect the intestinal mucus.
The washout material was centrifuged at 4000 r.p.m. for 20min
at 4◦C, the supernatant was harvested, and proteinase inhibitor
PMSF was added at ﬁnal concentration of 1mmol/L. Intestinal
mucus were stored at −80◦C for subsequent analysis. Tissues
were immediately placed in 10% neutral buﬀered formalin
(Fisher) (48 h, 4◦C) for histological studies. Peripheral blood
was taken from mice and centrifuged immediately at 1500 × g
for 15min at 4◦C to obtain serum. Serum samples were stored
at −80◦C until analyses. The concentrations of SIgA, Muc2,
defensins in intestinal mucus and serum cytokines and IgA were
assayed by ELISA (USCN, USA) according to the manufacture’s
instruction.
Morphological Examination and Histological
Analysis
The tissue samples of the distal ileum and proximal colon were
cut into ultra-thin cross sections, and they were ﬁxed in 10%
neutral buﬀered formalin, dehydrated, and paraﬃn-embedded.
The sections were hematoxylin/eosin (HE) stained and
examined under a phase-contrast microscope for morphological
characteristics. The histological damage was scored using the
following criteria: extent of destruction of normal epithelial
architecture (0, 1, 2, and 3, for normal, mild, moderate,
and extensive damage, respectively); presence and degree of
inﬂammatory inﬁltration (0, 1, 2, and 3, for normal, mild
localized inﬁltrate, mild generalized inﬁltrate, and severe
generalized inﬁltrate, respectively); presence of edema (0, 1,
2, and 3, for normal, mild, moderate, and extensive edema,
respectively); extent of vascular dilatation and congestion (0,
1, 2, and 3, for normal, mild, moderate, and extensive vascular
dilatation and congestion, respectively); presence or absence of
goblet cell depletion (0, absent; 1, present), presence or absence
of crypt abscesses (0, absent; 1, present). The scores for each
criterion were then summed with a maximum possible score of
14 as previously described (Gonzalez-Rey et al., 2006; Aguilera
et al., 2015; Grasa et al., 2015). To observe the microvilli, the
ultra-thin sections were stained with uranyl acetate and lead
citrate, and observed under a JEM-1400 TEM (Olympus, Japan).
Assessment of Gut Permeability
Gut permeability was measured as described previously with
minor modiﬁcations (Wang et al., 2001). The segments of distal
ileum and proximal colon were opened along the mesenteric
border and mounted in the Ussing chamber with an aperture
of 0.3 cm2. The chamber was connected to a VCC MC6
ampliﬁer, controlled and monitored using the Acquire and
Analyze software (V2.3.177 Physiologic Instruments, San Diego,
CA, USA). Experiments were carried out under current-clamp
(open-circuit) conditions as described previously (Lee et al.,
2007). Segments were incubated in oxygenated (95% O2; 5%
CO2) bicarbonate buﬀer at 37◦C. Tissue was equilibrated for
15min, thereafter a 3mA current pulse was applied across the
intestinal wall every 6 s for 30min. The trans-epithelial potential
wasmeasured and recorded by the Acquire and Analyze software,
and the change in potential induced by the current pulse was used
to calculate trans-epithelial resistance (TER) according to Ohm’s
Law. Higher values of TER represent lower gut permeability.
Immunohistochemical Staining
Four micro miter-thick cross sections of formalin-ﬁxed, paraﬃn-
embedded ileum and colon tissue were cut, deparaﬃnized,
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and subjected to a heat-induced epitope retrieval step. Slides
were rinsed in cool running water, washed in Tris-buﬀered
saline (pH7.4) before incubation with primary polyclonal
antibody against mouse Muc2 (USCN, USA, dilution 1:100)
overnight at 4◦C. For detection, rabbit anti-rat secondary
antibody was used followed by application of the peroxidase
kit (USCN, USA). Alkaline phosphatase was revealed by Fast
Red as chromogen and peroxidase was developed with a highly
sensitive diaminobenzidine (DBA) chromogenic substrate for
approximately 10min. Negative controls were performed by
omitting the primary antibody.
Statistical Analysis
The relative position and intensity of DNA bands on DGGE
proﬁles were used for principal component analysis (PCA) by
SPSS 16.0 statistical package (SPSS Inc. IL, USA). Statistical
analyses were performed using a two-tailed Student t-test,
with the assistance from GraphPad Prism Program (version
5.01, GraphPad Software Inc., USA). All values were expressed
as means ± standard deviation (SD) and the sample sizes.
Signiﬁcance was accepted at p < 0.05. If not otherwise speciﬁed,
statistical signiﬁcance was indicated as follows: ∗p < 0.05; ∗∗p <
0.01; ∗∗∗p < 0.001.
Results
Phenotype of BALB/c Mice after Ceftriaxone
Treatment
The experimental design is shown in Figure 1A. During
administration of ceftriaxone and over the course of recovery,
there were no incidences of mortality, and no signiﬁcant changes
in body weight were observed (Figure 1B). Compared with
control mice, the average size of the cecum in ceftriaxone-treated
mice was clearly larger (Figure 1C, top), and the ratio of cecal
weight to body weight, termed the cecal index, was signiﬁcantly
higher (Figure 1C, p = 0.002). After 7 days of ceftriaxone
treatment, antibiotic-associated diarrhea was observed in several
mice. The number of diarrheic mice did not reduce during the
3 days of transplantation, but instead increased continually. On
day 10, the average number of mice with diarrhea in each group
was 9, which was 30.00% of the total (Figure 1D). Symptoms
of diarrhea subsequently eased such that on day 16, signiﬁcant
diﬀerences in the percentage of diarrheic mice were observed
between the FMT/BCT groups and the SR group (p = 0.0213;
p = 0.0036), and between the BCT group and the FMT group
(p = 0.0381).
The Ceftriaxone-induced Intestinal Dysbiosis in
BALB/c Mice
DGGE ﬁngerprinting of cecal bacteria indicated a signiﬁcant
decrease of microbial diversity in ceftriaxone-treated mice. The
number of bands was reduced dramatically from 27.004 ± 1.000
to 7.667 ± 0.333 (Figure 2A, p = 0.0001). The data resulting
from DGGE analysis were subjected to PCA. Figure 2B shows
that distinct intestinal microbiota proﬁles are present in the
control mice and the ceftriaxone-treated mice. Samples taken
at day 8, right after the 7-day’s ceftriaxone administration, were
typically of the same group (D1, D2, D3), in contrast to samples
from the control mice (C1, C2, C3) which were treated sterile
water. The Log number of total bacteria per gram of cecum
content as assessed by q-PCR decreased from 10.942 ± 0.125
to 10.116 ± 0.070 (Figure 2C, p = 0.0049). Contrary to
the decreasing pattern of overall bacterial population, several
bands in the antibiotic-treated samples were more prominent
(Figure 2A, a–c). Sequence analysis of 16S rRNA gene fragments
of these bands revealed that a and b belonged to the genus
Enterococcus, and c showed highest similarity to Clostridium
species (Figure S2).
Population changes of 11 selected commensal bacterial
community members were also assessed by qPCR. Compared
with control mice, the number of Escherichia coli, Streptococcus
spp.,Veillonella spp., Bacteroides-Prevotella-Porphyromonas, and
Lactobacillus groups in the cecal contents of antibiotic-treated
mice decreased (Figure 2D, all p < 0.001). In contrast, because
of tolerance to ceftriaxone, the Log number of Enterococcus
spp. increased markedly from 7.732 ± 0.084 to 9.913 ±
0.178 (p = 0.0004), which is consistent with the DGGE
results.
Dysfunction of Intestinal Mucosal Barrier in Mice
Treated with Ceftriaxone
After sectioning and HE staining, ileum and colon samples
were observed under a microscope. Lesions and inﬂammatory
cells inﬁltration were observed in the ileum of ceftriaxone-
treated mice (Figure 3A, top). The integrity of microvilli in the
ileum of ceftriaxone-treated mice was perturbed, they arranged
irregularly, and in some instances were desquamated, and the
local membrane of the intestinal mucosal epithelial cell is
not complete (Figure S3). The ceftriaxone-treated mice had an
increase in hyperplasia of the colonic mucosa and distorted
tissue architecture; they had more severe vascular dilatation and
congestion than that of control mice (Figure 3A, bottom). The
histological score (Figure 3B) of both the ileum and colon in
mice treated with ceftriaxone was higher compared with control
mice.
The TER of the distal ileum and proximal colon in ceftriaxone-
treatedmice was reduced by 36.90 and 37.30% (Figure 3C, all p <
0.0001), respectively, compared with control mice, suggesting a
dramatic increase of intestinal permeability.
Figure 3D shows representative images of distal ileum
and proximal colon mucosae stained for Muc2 protein. The
expression of Muc2 was signiﬁcantly increased in ceftriaxone-
treated mice compared with control mice (Figure 3D). Muc2
protein content of the intestinal mucus also increased by
approximately 76.70% (p = 0.0001; Figure 3E). A signiﬁcant
decrease of SIgA expression (Figure 3F, p = 0.0001),
and increases of α-defensin 5 (p = 0.0003), α-defensin
6 (p = 0.0007), β-defensin 1 (p = 0.0360), and β-
defensin 2 (p = 0.0001) expression (Figure 3G) in the
intestinal ﬂuid of ceftriaxone-treated mice were observed.
In contrast, serum IgA levels were not aﬀected (p =
0.7269). The concentrations of inﬂammatory cytokines in
serum of ceftriaxone-treated mice increased (Figure 3H, all
p < 0.001).
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FIGURE 1 | Schematic overview of ceftriaxone treatment and
FMT/BCT. (A) To establish the intestinal dysbiosis model, BALB/c mice were
treated with ceftriaxone sodium for 7 days. After that, they were divided into
3 experimental groups: the spontaneous recovery group (SR), the fecal
microbiota transplantation group (FMT), and the bacterial consortium
transplantation group (BCT). The red vertical bars indicate sampling dates.
The recovery of intestinal ecosystem was observed for 3 weeks. (B) Mean
body weights, (C) Cecal index, and (D) The number of mice with diarrhea
were investigated respectively. ***p < 0.001; *, FMT compared with SR,
p < 0.05; , BCT compared with FMT, p < 0.05.
FMT and BCT Promote Re-establishment of the
Intestinal Microecology
FMT and BCT were performed on ceftriaxone-treated mice for
3 consecutive days. To perform BCT, we cultured a diverse
collection of 11 species from the fecal content of healthy mice
using selective media, including representatives of 5 phyla that
constitute the majority of the mammalian intestinal microbiota
(Firmicutes, Proteobacteria, Actinobacteria, Bacteroidetes, and
Fusobacteria; Table 1) (Mitsuoka, 1978). The proportion of each
group was deﬁned according to the fecal contents of control mice.
Because of the highly elevated population of Enterococcus spp.
in ceftriaxone-treated mice, this group was excluded from the
bacterial consortium.
The cecal microbiota in transplanted mice was analyzed by
DGGE and qPCR, and the results are shown in Figure 4. By
the ﬁrst week (4 days after transplantation), the diversity and
population (total numbers) of the microbiota in the FMT and
BCT groups was higher than in the SR group, but was still
diﬀerent from the control mice. There was a signiﬁcant diﬀerence
in the total number of bacteria between the FMT/BCT groups
and the SR group (p = 0.0427 and p = 0.0131, respectively).
The abundance of total bacteria in the BCT and FMT groups was
much lower in both of these groups than in the control group
(p = 0.0322). After 2 weeks of recovery, increasing patterns
of microbial diversity were observed in the SR, FMT, and BCT
groups, although the total bacterial populations were still lower
than the control group (p = 0.0037, p = 0.0050, and p = 0.0265,
respectively). Compared with the SR group, the total number of
microbes in the FMT/BCT group was larger (p = 0.0230; p =
0.0112). A signiﬁcant diﬀerence was detected between the total
number of microbes in the BCT and FMT groups (p = 0.0355).
After 3 weeks of recovery, both the diversity and population
of diﬀerent groups were similar to those of the control group,
suggesting that total recovery of the intestinal microbial structure
had occurred.
Population changes of the 11 selected bacterial groups were
also detected during recovery (Table 2). By the ﬁrst week, the
numbers of bacterial groups that had recovered (deﬁned as
having no signiﬁcant diﬀerence compared with control) in the
cecum of mice from the SR, FMT, and BCT were two, three, and
ﬁve, respectively. After 2 weeks, these numbers had increased
to ﬁve, six, and seven. By the third week, all of the selected
groups in the FMT and BCT groups had recovered to the level
of control mice, but the bacterial populations in the SR group
were variable; the populations of Eubacterium rectale-Clostricium
coccoides group and E. coli were less than the control, while in
contrast, the Enterococcus population was still larger.
Effects of FMT and BCT on the Repair of
Mechanical Barriers
Histological examination after 1 week of recovery showed that
there were still lesions and inﬂammatory cells inﬁltration in
distal ileum of the antibiotic treated mice (Figure 5A, top),
distorted tissue architecture and vascular congestion were also
detected (Figure 5A, bottom). While the destruction of the
mucosae appeared to have been substantially ameliorated in mice
receiving FMT or BCT, as less inﬂammatory cells inﬁltration, and
less distorted tissue architecture and vascular congestion were
detected, but these were not statistically signiﬁcant according
to the histological evaluation (Figure 5B, SR vs. FMT/BCT, all
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FIGURE 2 | Ceftriaxone induced intestinal dysbiosis in mice. (A)
DGGE pattern of the cecal microbial community of mice. C1–C3,
control mice, D1–D3, dysbiosis mice. a–c, the bands differ from control
were extracted from the DGGE gel and sequenced. (B) PCA of the
DGGE profile. Community similarity was calculated using the weighted
UniFrac distance metric, which incorporates phylogenetic as well as
relative abundance information. PC1 and PC2 account for 76.70% of
the variation. White dots, healthy mice; red dots, ceftriaxone-treated
mice. (C) The total population of intestinal microbes in control and
ceftriaxone-treated mice detected by qPCR. (D) The population of
selected commensal bacteria in control and ceftriaxone-treated mice
detected by qPCR. *p < 0.05; **p < 0.01; ***p < 0.001.
p > 0.05). After 2 weeks, the mucosae in the three diﬀerent
treatment groups had recovered to the level of the control group
(Figures S4, S5). The intestinal mucosal permeability of mice
decreased gradually during the recovery period (Figure 5C).
Compared with the SR group, the mucosal permeability of mice
in the FMT and BCT groups was signiﬁcantly lower after 1 (p =
0.0483, p = 0.0465) and 2 (p = 0.0384, p = 0.0228) weeks of
recovery.
Along with the increase in microbial density, the expression
level of Muc2 decreased gradually, and compared with the SR
group, Muc2 expression in the FMT and BCT groups was much
lower (Figure 5E). This is consistent with the ELISA results for
intestinal mucus in these mice (Figure 5D). Muc2 secretion in
the FMT and BCT groups on the 3rd and 7th day of recovery had
reached a level close to that observed in the control group, which
was signiﬁcantly lower than that in the SR group (p = 0.0385,
p = 0.0221), but there was no signiﬁcant diﬀerence observed
between the two transplanted groups.
Effects of FMT and BCT on the Immune Barrier
An increasing SIgA concentration was observed in the intestinal
mucus of mice during recovery (Figure 6A). Among the diﬀerent
experimental groups, the BCT group showed a clearly superior
recovery. On the 3rd and 7th day, the concentration of SIgA in
the BCT group was signiﬁcantly higher than in the SR group
(p = 0.0230, p = 0.0340), and was higher than the FMT group
by the 7th day (p = 0.0320). The concentration of SIgA in
the FMT group recovered faster than the SR group, although
the diﬀerences on the 3rd and 14th day were not signiﬁcant
statistically.
Higher concentrations of intestinal defensins (α-defensins 5
and 6, β-defensins 1 and 2) were detected in mice treated with
ceftriaxone (Figure 3G). During recovery, the secretion of these
defensins in the SR group did not decrease, but instead continued
to increase for at least 3 days, then decreased gradually until the
third week after treatment when levels reached those of controls
(Figures 6B–E). Transplantation of fecal microbiota or bacterial
consortium promoted reduction of α-defensins 5 and 6; on day
7, intestinal levels of α-defensin 5 in the FMT and BCT groups
were much lower than in the SR group (p = 0.0479, p = 0.0477).
The level of α-defensin 6 in the FMT and BCT groups started to
decrease immediately after transplantation, and was signiﬁcantly
lower than the SR group by the 3rd day (p = 0.0281, p = 0.0273).
By day 7, the level of α-defensin 6 in the BCT group was lower
than that in the FMT group (p = 0.0394). The levels of β-
defensin 1 in the FMT and BCT groups decreased gradually
after transplantation, but no signiﬁcant diﬀerences were detected
compared with the SR group (all p > 0.05). The concentration of
β-defensin 2 in the FMT and BCT groups increased dramatically
during transplantation to levels that were signiﬁcantly higher
than those in the SR group (p = 0.0130, p = 0.0460) and in the
control group (p = 0.0080, p = 0.0010), and this was followed
by a sharp decreasing. By the second week, β-defensin 2 levels in
the FMT and BCT groups had declined to the level seen in the
control group, which was signiﬁcantly lower than that in the SR
group (p = 0.0351, p = 0.0243).
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FIGURE 3 | The intestinal phenotype of ceftriaxone-treated mice.
(A) Representative patterns of HE-stained sections of distal ileum and
colon in mice. Magnification, ×200. The red arrows indicate inflammatory
cell infiltration, or vascular dilatation and congestion. (B) Histological
evaluation of the HE-stained sections. (C) Trans-epithelial resistance (TER)
of mouse distal ileum and colon was determined by measuring the
average changes in potential difference in response to 3μA current
generated across the tissue segments every 6 s for 30min. (D) Muc2
immunostaining in mouse distal ileum (top) and proximal colon (bottom),
Magnification, ×200. (E) The concentration of Muc2 in intestinal mucus of
mice. (F) The concentration of SIgA in intestinal mucus and serum IgA of
mice. (G) The concentration of defensins in intestinal mucus of mice. (H)
Serum levels of IL1-ß, IL-6, and TNF-α in mice. *p < 0.05; ***p < 0.001.
All the samples were taken at day 8.
During recovery, the concentration of serum IL-1β in all mice
gradually declined (Figure 6F). In the ﬁrst week, there were no
signiﬁcant diﬀerences observed between the three groups (all p >
0.05). By the second week, the reduction in serum IL-1β levels
in the microbiota-transplanted mice was more obvious than in
SR mice (SR vs. FMT, p = 0.0484; SR vs. BCT, p = 0.0484);
however, no signiﬁcant diﬀerence was observed between the FMT
and BCT groups (p > 0.05). The deceasing pattern of serum
IL-6 and TNF-α levels observed during recovery was similar to
that of IL-1β (Figures 6G,H). After 3 weeks, the serum levels
of inﬂammatory cytokines in all the groups had reduced to the
normal level (i.e., p > 0.05 compared with the control group).
Discussion
As shown in many studies (Wlodarska et al., 2011; Aguilera et al.,
2015; Grasa et al., 2015), treatment with antibiotics has signiﬁcant
eﬀects on the structure of the intestinal microbiota. Our study
also demonstrated that intragastric ceftriaxone induced severe
dysbiosis in mice, and both the population and diversity of
microbes were disturbed in the cecum of antibiotic-treated mice.
The cecum is connected to the ileum and is considered to be
the beginning of the large intestine. There are large numbers
of bacteria dwelling in this cavity, therefore, we analyzed the
bacterial contents in the cecum to investigate the eﬀects of
microbiota transplantation in the small and large intestines.
Consequently, the barrier function of the distal ileum and colon
was evaluated. The spontaneous recovery of intestinal microbiota
in mice after antibiotic treatment takes at least 3 weeks to become
restored to the previous level (Lawley et al., 2009), and in many
cases, the recovery is unpredictable and incomplete (Dethlefsen
and Relman, 2011). We observed that, during the ﬁrst week of
recovery, compared with SRmice, the population and diversity of
intestinal microbiota in the cecum in the FMT and BCT groups
were larger. By the end of the second week, there was a signiﬁcant
diﬀerence in total bacterial abundance between the FMT and
BCT groups, suggesting that BCT can accelerate the increase of
microbial diversity and population in the mouse intestine.
Unexpectedly, histological lesions were detected in the small
intestine of mice treated with ceftriaxone, and vascular dilation
and congestion were observed in the large intestine. These
observations collectively suggest a proinﬂammatory state of
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FIGURE 4 | The recovery of intestinal microbiota in different mice
groups. (A) PCA of the cecal microbiota in different experimental mice
groups during the 3-week recovery. PC1 and PC2 account for 66.66, 59.62,
and 51.26% of the variation in different weeks. Each symbol represents one
microbiota (dot). White dots, healthy mice; red dots; SR mice, blue dots,
FMT mice; green dots, BCT mice. (B) The population of total intestinal
microbes in different mice groups detected by qPCR. *p < 0.05; w, week(s)
after ceftriaxone treatment.
the mouse intestine. The disrupted organization of microvilli
and increased permeability of the intestinal mucosa suggest a
deﬁciency in nutrient absorption (Bennett et al., 2014), and risk
of bacterial endotoxin translocation (Strowski andWiedenmann,
2009). These ﬁndings were conﬁrmed by the elevation of
circulatory proinﬂammatory cytokines, which suggested that the
local inﬂammatory responses in the intestine aﬀected the changes
in systemic immunity. Antibiotics are often used to create germ-
free conditions; however, the intestinal balance of microbiota
is disrupted, leading to greater susceptibility to infection in
the intestine. Our result seems to diﬀer from the traditional
view; however, it also suggested the importance of protecting
commensal bacteria. As we can see from the data, compared
with SR, FMT and BCT ameliorated the increased permeability
of the intestinal mucosa, which indicates an important role of
the microbiota in maintaining the normal intestinal epithelial
structure.
The intestinal mucosal surfaces are coated with a layer of
viscous mucus that protects the epithelial cells from chemical,
enzymatic, microbial, and mechanical insult. Muc2 is the major
component of the mucus layer in the small and large intestines.
Increased intestinal mucus production in mice with dysbiosis
may be one of the causes of antibiotic-associated diarrhea
because hypersecretion of glycoproteins by the intestinal mucosa
is observed during acute infection (Hasnain et al., 2011). It
is reported that Muc2 helps the disassociation of pathogenic
and normal microbiota from the intestinal mucosa, and thus
prevents infectious colitis (Bergstrom et al., 2010), and Muc2-
deﬁcient mice develop spontaneous colitis (Wenzel et al., 2014).
We therefore infer that increased Muc2 is a compensatory
secretion from the mucosal goblet cells in the absence of
the microbial barrier. Another possible reason is that many
inﬂammatory factors such as IL-1β, IL-6, interferons, and TNF-α
can quickly upregulate expression of mucins (Linden et al., 2008),
and that ceftriaxone-induced dysbiosis may have caused the
observed increase in inﬂammatory cytokines, thus stimulating
the secretion of Muc2. During the 3 days of FMT and BCT,
the expression and secretion of Muc2 decreased rapidly and
remained stable until the end of the experiment. On the one hand,
metabolites of the intestinal microbiota can stimulate expression
of mucins by goblet cells (Lutgendorﬀ et al., 2008). On the
other hand, they can also rapidly metabolize excessive mucins
(Macfarlane et al., 2005); therefore, the decreased bacterial
population may also contribute to the increased amount of
Muc2 in the intestinal mucus. This illustrates that the intestinal
microbiota play crucial roles in regulating the equilibrium of
intestinal mucus.
Intestinal mucus provides a large matrix for a rich array
of antimicrobial molecules such as SIgA and defensins. They
are essential components of the innate immune system and
contribute greatly to intestinal barrier function. SIgA is the
most abundant immunoglobulin found in intestinal mucus
(Corthesy, 2013). Our results showed that SIgA secretion in
ceftriaxone-treated mice was signiﬁcantly lower than in control
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mice, suggesting a signiﬁcant reduction in the protective ability
of the intestinal mucosa against exogenous bacterial infection.
SIgA molecules are assembled from proteins expressed in two
cell lineages. The heavy and light chains and the J chain are
produced in plasma cells, whereas the secretory component
(SC) is associated with the immunoglobulin complex during
transcytosis across the epithelial layer (Corthesy and Spertini,
1999). When measuring serum levels of IgA, we detected no
signiﬁcant diﬀerence between the ceftriaxone-treated mice and
healthy controls (Figure 3E). This suggests that ceftriaxone-
induced dysbiosis may have aﬀected the expression of SC at
the intestinal epithelial layer, resulting in reduced SIgA levels in
the intestine. Compared with SR, the FMT and BCT methods
restored the secretion of SIgAmore eﬀectively, and there was also
a signiﬁcant diﬀerence between FMT and BCT.
Defensins are endogenous antibiotics with microbicidal
activity against a wide range of microbes. They provide a
critical mucosal defense and can signal to various components
of the innate and adaptive immune systems (Wehkamp et al.,
2005). When the intestinal ecosystem is in balance, epithelial
cells produce defensins such as α-defensins 5 and 6, and β-
defensin 1, as a strong chemomechanical barrier to control the
intestinal microbiota and maintain immunological homeostasis.
Upregulation of α-defensin 5 is a predictor of chronic/relapsing
pouchitis, and can mediate shifts in the composition of the
microbiota that favor inﬂammation (Scarpa et al., 2012). During
inﬂammation or infection, additional defensins such as β-
defensin 2 and 3 are induced as a type of “demand system”
(Semple and Dorin, 2012). Here, we observed that the levels
of α-defensins 5 and 6, and of β-defensins 1 and 2, in the
intestinal mucus of ceftriaxone-treated mice were signiﬁcantly
higher than those of control mice, which suggests that dysbiosis
of the intestinal microbiota had caused a susceptible state in
the mouse intestine. These increased small peptides may further
exert their antimicrobial activity toward intestinal microbiota
and cause more severe dysbiosis. As shown in Figure 6, in SR
mice, these defensins continuously increased for at least 1 week
after antibiotic administration was stopped. In contrast, levels of
α-defensins 5 and 6, and β-defensin 1, decreased gradually after
FMT or BCT, and marked diﬀerences were detected between the
SR group and the FMT/BCT groups by the ﬁrst week.
The secretion of β-defensin 2 in mouse intestine during
FMT/BCT was aﬀected in a negative feedback pattern. It
increased rapidly, reaching the highest level at day 3, and this
was followed by a sharp decline to the control level within
2 weeks. A systemic immune response has previously been
described in patients treated with FMT, including fever and a
temporary increase of C-reactive protein (Vermeire et al., 2012;
Angelberger et al., 2013). Our results suggest that transplantation
of microbes may aggravate the inﬂammatory responses in mice
with intestinal dysbiosis, and the impact of the BCT method
seems stronger. Nevertheless, compared with FMT and BCT, the
natural recovery of β-defensin 2 in ceftriaxone-treated mice took
longer, suggesting a longer state of susceptibility in the mouse
intestinal mucosa.
Proinﬂammatory cytokines such as IL-1β, IL-6, and TNF-α
are well recognized as mediators during the onset of disease,
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FIGURE 5 | Post-FMT or BCT changes of the mechanical barriers in
intestinal mucosa of different mice groups. (A) Representative
patterns of HE-stained sections of distal ileum and proximal colon in mice
after 1 week recovery. Magnification, ×200. The red arrows indicate
inflammatory cell infiltration, or vascular dilatation and congestion. (B)
Histological analysis was performed after 1 week recovery. **p < 0.001
compared with control. (C) TER of distal ileum in different mice groups
detected after 1 week recovery, *, FMT compared with SR, p < 0.05. The
X axes indicate days after ceftriaxone treatment. (D) The concentration of
Muc2 in intestinal mucus of mice. *, FMT compared with SR, p < 0.05.
All values are means ± SD of 5 mice per group. (E) Muc2
immunostaining in mouse distal ileum and proximal colon.
FIGURE 6 | Post-FMT or BCT changes of intestinal SIgA,
defensins and serum inflammatory cytokines. The concentration of
SIgA (A), α-defensin 5 (B), 6 (C), β-defensin 1 (D), and 2 (E) in
intestinal mucus of mice, and the serum levels of IL1-β (F), IL-6 (G),
TNF-α (H) in mice post-FMT or BCT were measured by ELISA. Values
are means ± SD of 5 mice per group. *, FMT compared with SR p
< 0.05. , BCT compared with FMT p < 0.05. The X axes indicate
days after ceftriaxone treatment.
and they play important roles in the local inﬂammatory reaction
and immune response (Lim et al., 2014). As we showed,
the levels of these cytokines were elevated after ceftriaxone
treatment, which suggested that ceftriaxone-induced dysbiosis
altered the systemic immune networks in these mice. These
changes may correlate with a reduction in commensal bacteria
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and overgrowth of opportunistic pathogens. With the re-
establishment of the microbial structure, levels of IL-1 β, IL-6,
and TNF-α reduced gradually. Compared with the SR group,
the FMT and BCT treatments promoted the reduction of
proinﬂammatory cytokines, but no signiﬁcant diﬀerence was
found between these two groups. In addition, studies have shown
that the stimulation of proinﬂammatory cytokines is closely
associated with the expression of mucin (Ahn et al., 2005)
and defensins (Krisanaprakornkit et al., 2000) by the intestinal
mucosa, as well as an increase in mucosal permeability (Al-Sadi
et al., 2008). The observed up- and down-regulation of cytokine
levels are consistent with the changes of Muc2 and defensin levels
during ceftriaxone treatment and over the course of recovery.
Overall, based on a short-term study, we have systematically
examined changes in the intestinal mucosal phenotype,
permeability, mucin expression, and expression of infection-
related immune factors in BABL/c mice before and after
transplantation with either fecal microbiota or a consortium
of isolated commensal bacteria from healthy mice. Although
limited by the low number of mice used at each collecting
time point, our data still show that disruption of intestinal
microbial homeostasis aﬀects mucosal permeability, mucin
expression, and the network of immune molecules. The FMT
and BCT methods promote re-establishment of the intestinal
microbial structure, and contribute to the temporal and spatial
interplay between microbiota and intestinal mucosal barriers.
The eﬀects of the BCT method were comparable to those of
FMT, and especially eﬃcient in normalizing the secretion levels
of SIgA and defensins. As a result of signiﬁcant inter-individual
variation and the possible risk of disease transmission, FMT is
not regarded as a safe therapy, and there are also some aesthetic
and ethical challenges associated with its use. In contrast,
the bacteria used for BCT are puriﬁed from healthy donors,
and the proportion of each bacterium can be standardized or
individualized according to the diﬀerent level of dysbiosis. BCT
is therefore a viable alternative to conventional FMT for various
gastrointestinal diseases. However, our results also suggest
that transplantation of bacterial consortia may temporarily
aggravate the inﬂammatory responses in recipients, and further
detailed long-term studies should be conducted to evaluate these
eﬀects.
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